DOCS

Doximity Inc

Add to Watchlist

Advanced Chart

65.830

+0.7(1.075%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

65.850

Open

64.960

VWAP

65.01

Vol

154.69K

Mkt Cap

12.20B

Low

64.510

Amount

10.06M

EV/EBITDA(TTM)

45.40

Total Shares

185.43M

11.36B

EV/OCF(TTM)

38.62

P/S(TTM)

22.28

Doximity, Inc. provides a digital platform for the United States medical professionals. It offers marketing, hiring, and workflow solutions to pharmaceutical manufacturers, health systems, medical recruiting firms, and other healthcare companies. Its marketing solutions enable its pharmaceutical and health system customers to get the right content, services, and peer connections to the right medical professionals through a variety of modules. Its hiring solutions provide digital recruiting capabilities to health systems and medical recruiting firms, enabling them to identify, connect with, and hire from its network of both active and passive medical professional candidates, who might otherwise be missed through traditional recruiting channels. Its workflow solutions include its telehealth, on-call scheduling, and AI-powered workflow tools, are designed to help clinicians streamline their clinical workflow, reduce their administrative burden, and connect with patients and colleagues.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q4

FY2026Q3

FY2026Q2

150.70M

+8.98%

0.336

-11.7%

180.06M

+6.79%

0.446

-0.88%

157.25M

+14.92%

0.376

+25.32%

Estimates Revision

The market is revising Upward the revenue expectations for Doximity, Inc. (DOCS) for FY2026, with the revenue forecasts being adjusted by 1.2% over the past three months. During the same period, the stock price has changed by 22.43%.

Revenue Estimates for FY2026

Revise Upward

+1.2%

In Past 3 Month

EPS Estimates for FY2026

Revise Upward

+4.75%

In Past 3 Month

Stock Price

Go Up

+22.43%

In Past 3 Month

15 Analyst Rating

-3.98% Downside

Wall Street analysts forecast DOCS stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for DOCS is 63.21 USD with a low forecast of 50.00 USD and a high forecast of 80.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

7 Buy

8 Hold

0 Sell

Moderate Buy

-3.98% Downside

Current: 65.830

Low

50.00

Averages

63.21

High

80.00

-3.98% Downside

Current: 65.830

Low

50.00

Averages

63.21

High

80.00

Canaccord

Richard Close

Hold

maintain

$50 -> $59

2025-08-08

Reason

Canaccord

Richard Close

Price Target

$50 -> $59

2025-08-08

maintain

Hold

Reason

Canaccord analyst Richard Close raised the firm's price target on Doximity to $59 from $50 and keeps a Hold rating on the shares. The firm said Doximity posted yet another strong quarter, besting Street estimates and the high- end end of quarterly guidance ranges by a wide margin. FY'26 guidance was raised by essentially the same margin as the beat, implying substantive slow down in growth in the second half of the fiscal year, though there is likely a fair amount of conservatism baked in.

Wells Fargo

Equal Weight

maintain

$62 -> $65

2025-08-08

Reason

Wells Fargo

Price Target

$62 -> $65

2025-08-08

maintain

Equal Weight

Reason

Wells Fargo raised the firm's price target on Doximity to $65 from $62 and keeps an Equal Weight rating on the shares. The firm says the Q1 beat and raise reflects solid business momentum and echoes conclusions from its preview ahead of earnings print. AI strategy is taking shape as debuted AI Scribe and acquired Pathway AI reinforces platform engagement and monetization prospects, Wells adds.

Raymond James

Outperform

maintain

$65 -> $75

2025-08-08

Reason

Raymond James

Price Target

$65 -> $75

2025-08-08

maintain

Outperform

Reason

Raymond James raised the firm's price target on Doximity to $75 from $65 and keeps an Outperform rating on the shares. Doximity's Q1 results showed an impressive top-line beat and above consensus outlook, with a conservative guidance for the back half of the year, the analyst tells investors in a research note. The firm is encouraged by commentary on the mid-year buying and the impact of the customer portal.

Morgan Stanley

Equal Weight

maintain

$60 -> $62

2025-08-08

Reason

Morgan Stanley

Price Target

$60 -> $62

2025-08-08

maintain

Equal Weight

Reason

Morgan Stanley raised the firm's price target on Doximity to $62 from $60 and keeps an Equal Weight rating on the shares. Doximity beat and raised despite macro cross-currents, notes the analyst, who sees momentum in the business and a strong balance sheet "allowing Doximity to go on offense in completing a strategic technology tuck-in."

Needham

Buy

maintain

$67 -> $75

2025-08-08

Reason

Needham

Price Target

$67 -> $75

2025-08-08

maintain

Buy

Reason

Needham raised the firm's price target on Doximity to $75 from $67 and keeps a Buy rating on the shares. The company reported strong Q1 results highlighted by early success in the upsell season, driven by new products, the analyst tells investors in a research note. The firm is especially bullish on Doximity's two new AI innovations, Scribe and Pathway, which extend its functionality with offerings that are in high demand among physicians in 2025, Needham added.

Wells Fargo

Equal Weight

maintain

$55 -> $62

2025-08-04

Reason

Wells Fargo

Price Target

$55 -> $62

2025-08-04

maintain

Equal Weight

Reason

Wells Fargo raised the firm's price target on Doximity to $62 from $55 and keeps an Equal Weight rating on the shares. The firm is also raising estimates on product-led growth tailwinds, drug pipeline, and checks pointing to healthy pharma commercial activity. This should translate into positive near-term momentum on earnings, but valuation keeps Wells on the sidelines.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Doximity Inc (DOCS.N) is 42.67, compared to its 5-year average forward P/E of 58.43. For a more detailed relative valuation and DCF analysis to assess Doximity Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Fair

5Y Average PE

58.43

Current PE

42.67

Overvalued PE

106.37

Undervalued PE

10.48

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Fair

5Y Average EV/EBITDA

38.26

Current EV/EBITDA

32.09

Overvalued EV/EBITDA

68.50

Undervalued EV/EBITDA

8.03

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

17.48

Current PS

18.80

Overvalued PS

26.97

Undervalued PS

7.99